AbbVie's stock plummets over 12% after schizophrenia drug flops in ...

AbbVie's stock price fell over 12% after emraclidine failed to meet its primary endpoints in the company's Phase II schizophrenia programme.

AbbVie's stock price fell over 12% after emraclidine, an investigational anti-psychotic being evaluated for the treatment of schizophrenia, ...

AbbVie Shares Plummet 12% as Cerevel Schizophrenia Asset Fails ...

The centerpiece drug of AbbVie's nearly $9 billion acquisition of Cerevel Therapeutics has failed in two Phase II clinical trials for patients ...

AbbVie Tumbles After New Schizophrenia Drug Fails in Two Trials

AbbVie Inc. shares fell the most in more than four years after two mid-stage trials of its drug to treat schizophrenia failed to meet their ...

AbbVie Stock Slides on Schizophrenia Drug Study Failure - WSJ

AbbVie said a recently acquired drug candidate for schizophrenia missed the key goal in mid-stage studies, pushing its stock sharply lower.

AbbVie Stock Sinks After Schizophrenia Drug Trials Disappoint

Shares of AbbVie plummeted Monday after the company said its schizophrenia drug Emraclidine missed key goals in a pair of trials.

AbbVie's stock plummets over 12% after schizophrenia drug flops in ...

AbbVie's stock price fell over 12% after emraclidine, an investigational anti-psychotic being evaluated for the treatment of schizophrenia, ...

AbbVie's closely watched schizophrenia drug fails two studies ...

AbbVie shares fell over 12% on Monday after an experimental schizophrenia drug the company acquired last year failed two mid-stage studies, ...

AbbVie's Surprise Schizophrenia Flop, AstraZeneca's China Drama ...

A tale of two multi-billion schizophrenia deals, AstraZeneca touts strong sales while deflecting questions about an investigation into China ...

AbbVie Shares Plunge as Experimental Schizophrenia Drug Flops ...

This news came as a rude awakening for investors, who watched AbbVie's stock drop by more than 12% in early trading, marking the largest ...

AbbVie's $9B bet collapses as closely watched schizophrenia drug ...

Still, AbbVie investors may not see much of a silver lining. Company shares were down more than 12% Monday morning, representing one of the ...

AbbVie Trials for Schizophrenia Drug Fail | Perigon

AbbVie Trials for Schizophrenia Drug Fail ; AbbVie's stock plummets over 12% after schizophrenia drug flops in Phase II trials. in 12h. AbbVie's ...

AbbVie Stock Tumbles on Failed Schizophrenia Drug ... - Barron's

Shares of AbbVie were getting hammered Monday after the drug maker said two Phase 2 trials of its experimental schizophrenia drug showed no ...

On Wall Street, 'flat out' failure of AbbVie schizophrenia drug leaves ...

AbbVie shares were down more than 12% Monday, erasing roughly $40 billion in value. Among large pharmaceutical companies, it's one of the ...

Ross Law, Author at Clinical Trials Arena

AbbVie's stock price fell over 12% after emraclidine, an investigational anti-psychotic being evaluated for the treatment of schizophrenia, failed to… Customer- ...

AbbVie tumbles after new schizophrenia drug fails trials

AbbVie Inc. shares fell the most in more than four years after two mid-stage trials of its drug to treat schizophrenia failed to meet their ...

ABBVIE INC. (ABBV) Stock, Price, News, Quotes, Forecast ... - MSN

AbbVie's stock plummets over 12% after schizophrenia drug flops in Phase II trials. AbbVie's stock plummets over 12% after schizophrenia drug flops in Phase ...

AbbVie Shares Fall Premarket After Schizophrenia Drug Study Failure

AbbVie shares, which closed Friday at $199.50, were recently down more than 10% to $178.99 in premarket trading, while shares of Bristol ...

AbbVie Inc (ABBV) Stock Price & News - Google Finance

AbbVie's stock plummets over 12% after schizophrenia drug flops in Phase II trials · Seeking Alpha. 3 days ago. Bristol-Myers upgraded at Leerink after AbbVie ...

ABBV - Abbvie Inc Stock Price and Quote - FINVIZ.com

AbbVie Stock Tumbles on Failed Schizophrenia Drug Studies. Bristol Myers Jumps. (Barrons.com). 10:12AM · Bristol Myers Rockets 12% After AbbVie's ...